Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab-based chemoradiotherapy maintenance for oligometastatic cervical cancer
ChiCTR2500098352Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, bevacizumab, paclitaxel, carboplatin and cisplatin in Cervical Cancer (CC), sponsored by Dongguan People's Hospital. Primary endpoints: Progression-free survival and Safety. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
cadonilimabbevacizumabpaclitaxelcarboplatincisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500098352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098352.